Approximately 10% of CF patients carry cystic fibrosis transmembrane conductance regulator (CFTR) nonsense mutations that cannot be treated with any FDA-approved CFTR modulators, and around half of these mutations are correctable by ABE24 (Supplementary Fig. 4a). The gene discussed is CFTR; the disease is cystic fibrosis.